Pfizer’s RSV vaccine receives EC approval to protect infants and older adults
The decision follows a recent recommendation from the European Medicines Agency’s human medicines committee
Read More
Tag: RSV
Pfizer’s maternal RSV vaccine receives FDA approval
The decision allows Abrysvo to be given to those who are 32 to 36 weeks into their pregnancy
Read More
New data reinforces AstraZeneca and Sanofi’s nirsevimab as effective RSV immunisation
Nirsevimab is the first investigational immunisation designed to protect all infants across the RSV season with a single dose
Read More
First RSV vaccine trial for infants offers significant results
The phase 3 MELODY study reveals that nirsevimab vaccine reduces lower respiratory tract infections
Read More
Quidel gains CE mark for combined COVID-19, flu and RSV diagnostic test
Company’s molecular testing platform and first assay panel can now be marketed in the EU
Read More
GSK launches late-stage study of RSV vaccine in pregnant mothers
Shot will be evaluated in pregnant mothers and their newborn infants
Read More
GSK’s RSV vaccine candidates score positive phase I/II results
Vaccine candidates prove promising for maternal immunisation and for older adults
Read More
Nirsevimab shows promise for long-term RSV protection
The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
Read More
Breakthrough status for Janssen’s RSV vaccine
RSV is a highly prevalent, very contagious respiratory infection and a leading cause of bronchitis and pneumonia.
Read More
AstraZeneca divests US rights to Synagis
Swedish Orphan Biovitrum AB has entered into an agreement to buy US rights to AstraZeneca’s Synagis, licensed for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV).
Read More
Pfizer begins testing RSV vaccine in healthy adults
Pfizer has kicked off an early stage trial of an experimental vaccine against respiratory syncytial virus (RSV) in healthy adult volunteers.
Read More
Regeneron drops RSV therapy on trial failure
Regeneron Pharmaceuticals is pulling the plug on an experimental therapy in development for preventing respiratory syncytial virus (RSV) infection in infants, after a disappointing performance in a late-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
